001     284605
005     20240229155053.0
024 7 _ |a 10.1016/j.euo.2023.09.008
|2 doi
024 7 _ |a pmid:37806841
|2 pmid
024 7 _ |a altmetric:155203594
|2 altmetric
037 _ _ |a DKFZ-2023-02025
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Krilaviciute, Agne
|0 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
|b 0
|e First author
|u dkfz
245 _ _ |a Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer.
260 _ _ |a Amsterdam
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1702549363_27018
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C130#LA:C130#LA:C020# / 2023 Dec;6(6):566-573
520 _ _ |a Annual digital rectal examination (DRE) is recommended as a stand-alone screening test for prostate cancer (PCa) in Germany for 45+ yr olds. DRE diagnostic performance in men as young as 45 yr old has not been proved by a screening trial.To determine DRE diagnostic performance in a screening trial.This analysis was conducted within the multicentric, randomized PROBASE trial, which enrolled >46 000 men at age 45 to test risk-adapted prostate-specific antigen (PSA) screening for PCa.(1) DRE was analyzed as a one-time, stand-alone screening offer at age 45 in 6537 men in one arm of the trial and (2) PCa detection by DRE was evaluated at the time of PSA-screen-driven biopsies (N = 578).(1) True-/false-positive detection rates of DRE as compared with PSA screening and (2) DRE outcome at the time of a prostate biopsy were evaluated.(1) A prospective analysis of 57 men with suspicious DRE at age 45 revealed three PCa. Detection rate by DRE was 0.05% (three of 6537) as compared with a four-fold higher rate by PSA screening (48 of 23 301, 0.21%). The true-positive detection rate by DRE relative to screening by PSA was 0.22 (95% confidence interval [CI] = [0.07-0.72]) and the false-positive detection rate by DRE was 2.2 (95% CI = [1.50-3.17]). (2) Among PSA-screen-detected PCa cases, 86% had unsuspicious DRE (sensitivity relative to PSA was 14%), with the majority of these tumors (86%) located in the potentially accessible zones of the prostate as seen by magnetic resonance imaging.The performance of stand-alone DRE to screen for PCa is poor. DRE should not be recommended as a PCa screening test in young men. Furthermore, DRE does not improve the detection of PSA-screen-detected PCa.Our report demonstrated the poor diagnostic performance of digital rectal examination in the screening for prostate cancer in young men.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Digital rectal examination
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
650 _ 7 |a Screening
|2 Other
700 1 _ |a Becker, Nikolaus
|0 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
|b 1
|e First author
|u dkfz
700 1 _ |a Lakes, Jale
|b 2
700 1 _ |a Radtke, Jan Philipp
|b 3
700 1 _ |a Kuczyk, Markus
|b 4
700 1 _ |a Peters, Inga
|b 5
700 1 _ |a Harke, Nina N
|b 6
700 1 _ |a Debus, Jürgen
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 7
|u dkfz
700 1 _ |a Koerber, Stefan A
|b 8
700 1 _ |a Herkommer, Kathleen
|b 9
700 1 _ |a Gschwend, Jürgen E
|b 10
700 1 _ |a Meissner, Valentin H
|b 11
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 12
|u dkfz
700 1 _ |a Seibold, Petra
|0 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
|b 13
|u dkfz
700 1 _ |a Kristiansen, Glen
|b 14
700 1 _ |a Hadaschik, Boris
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Arsov, Christian
|b 16
700 1 _ |a Schimmöller, Lars
|b 17
700 1 _ |a Giesel, Frederik Lars
|b 18
700 1 _ |a Antoch, Gerald
|b 19
700 1 _ |a Makowski, Marcus
|b 20
700 1 _ |a Wacker, Frank
|b 21
700 1 _ |a Schlemmer, Heinz-Peter
|0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
|b 22
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 23
|e Last author
|u dkfz
700 1 _ |a Albers, Peter
|0 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
|b 24
|e Last author
|u dkfz
773 _ _ |a 10.1016/j.euo.2023.09.008
|g p. S2588931123002031
|0 PERI:(DE-600)2945338-0
|n 6
|p 566-573
|t European urology oncology
|v 6
|y 2023
|x 2588-9311
909 C O |p VDB
|o oai:inrepo02.dkfz.de:284605
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)78a9df7108a5b079145be1cb1ab6a315
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)1573258b58c33f1922ca9719d0c8c4ab
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2023
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR UROL ONCOL : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR UROL ONCOL : 2022
|d 2023-08-25
920 2 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
920 2 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 1
920 1 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 1
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l C060 Biostatistik
|x 2
920 1 _ |0 I:(DE-He78)ED01-20160331
|k ED01
|l DKTK Koordinierungsstelle Essen/Düsseldorf
|x 3
920 1 _ |0 I:(DE-He78)E010-20160331
|k E010
|l E010 Radiologie
|x 4
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 5
920 0 _ |0 I:(DE-He78)C130-20160331
|k C130
|l Personalisierte Früherkennung des Prostatakarzinoms
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C130-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)ED01-20160331
980 _ _ |a I:(DE-He78)E010-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21